X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DISHMAN PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DISHMAN PHARMA NOVARTIS/
DISHMAN PHARMA
 
P/E (TTM) x 361.1 25.1 1,439.2% View Chart
P/BV x 17.8 3.3 531.2% View Chart
Dividend Yield % 1.6 0.7 244.4%  

Financials

 NOVARTIS   DISHMAN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
DISHMAN PHARMA
Mar-16
NOVARTIS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs982374 262.3%   
Low Rs556129 431.5%   
Sales per share (Unadj.) Rs252.9197.8 127.9%  
Earnings per share (Unadj.) Rs62.121.2 293.0%  
Cash flow per share (Unadj.) Rs63.334.7 182.3%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.8 163.6%  
Book value per share (Unadj.) Rs363.6179.9 202.1%  
Shares outstanding (eoy) m31.9680.69 39.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.01.3 239.0%   
Avg P/E ratio x12.411.9 104.3%  
P/CF ratio (eoy) x12.27.2 167.7%  
Price / Book Value ratio x2.11.4 151.2%  
Dividend payout %16.19.4 170.6%   
Avg Mkt Cap Rs m24,58020,306 121.1%   
No. of employees `0000.80.8 90.7%   
Total wages/salary Rs m1,8015,355 33.6%   
Avg. sales/employee Rs Th10,748.919,252.7 55.8%   
Avg. wages/employee Rs Th2,395.26,459.5 37.1%   
Avg. net profit/employee Rs Th2,641.12,064.1 128.0%   
INCOME DATA
Net Sales Rs m8,08315,961 50.6%  
Other income Rs m829265 312.5%   
Total revenues Rs m8,91316,226 54.9%   
Gross profit Rs m2344,103 5.7%  
Depreciation Rs m371,091 3.4%   
Interest Rs m2944 0.2%   
Profit before tax Rs m1,0252,334 43.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m171 1,518.2%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m752624 120.6%   
Profit after tax Rs m1,9861,711 116.1%  
Gross profit margin %2.925.7 11.3%  
Effective tax rate %73.426.7 274.5%   
Net profit margin %24.610.7 229.2%  
BALANCE SHEET DATA
Current assets Rs m12,67811,018 115.1%   
Current liabilities Rs m2,4339,517 25.6%   
Net working cap to sales %126.79.4 1,347.8%  
Current ratio x5.21.2 450.1%  
Inventory Days Days33110 29.6%  
Debtors Days Days2235 64.6%  
Net fixed assets Rs m6916,304 0.4%   
Share capital Rs m160161 99.0%   
"Free" reserves Rs m11,46012,907 88.8%   
Net worth Rs m11,62114,516 80.1%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m14,40029,805 48.3%  
Interest coverage x570.53.5 16,436.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 104.8%   
Return on assets %13.88.9 154.9%  
Return on equity %17.111.8 145.0%  
Return on capital %23.617.5 134.5%  
Exports to sales %0.724.8 3.0%   
Imports to sales %18.63.7 497.6%   
Exports (fob) Rs m603,956 1.5%   
Imports (cif) Rs m1,503596 252.0%   
Fx inflow Rs m1864,952 3.8%   
Fx outflow Rs m1,821697 261.3%   
Net fx Rs m-1,6354,255 -38.4%   
CASH FLOW
From Operations Rs m2,5312,786 90.8%  
From Investments Rs m-8,270-1,529 540.9%  
From Financial Activity Rs m-386-941 41.0%  
Net Cashflow Rs m-6,125316 -1,935.7%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 3.7 54.1%  
FIIs % 1.6 12.7 12.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 22.1 97.3%  
Shareholders   41,647 46,261 90.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  ALEMBIC LTD  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 22, 2018 03:37 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ORCHID PHARMA LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS